NEW YORK (GenomeWeb) – Epigenomics on Thursday lowered its revenue guidance for 2017 to a range of between €1 million ($1.1 million) and €1.5 million from a previous guidance of about €2.5 million.

The firm attributed the change to lower-than-expected revenues for the first half of the year, about €500,000, and added that it anticipates a continued lack of reimbursement coverage for the rest of the year in the US. In May the firm reported a 5 percent drop in revenues for the first quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.